Short Summary
The PTAB issued a final written decision in IPR2023‑01075, finding that none of the 24 challenged claims of Samsung Display’s OLED pixel‑arrangement patent (U.S. 11,594,578) were unpatentable. The Board rejected BOE’s obviousness arguments based on Matthies, Yamada, and Hong, concluding no teaching of a "pixel defining layer" existed. All claims remain in force.
Detailed Summary
In IPR2023‑01075, BOE Technology Group and its affiliates challenged 24 claims of Samsung Display’s U.S. Patent No. 11,594,578, which covers a pixel arrangement structure for OLED displays. The petition relied on three prior‑art references—Matthies (U.S. Pat. 6,897,855 B1), Yamada (U.S. Pat. 6,366,025 B1), and Hong (U.S. Patent Application 2011/0234550 A1)—to argue that the claims were obvious under 35 U.S.C. § 103. Central to the argument was the alleged “pixel defining layer,” which the petitioner claimed could be inferred from the references. The Administrative Patent Judges found no explicit disclosure of such a layer in any reference and rejected the asserted motivation to combine the teachings. Consequently, the Board determined that BOE had not met its burden of proof, and all challenged claims were found patentable. The decision affirms the validity of the patent and closes the inter‑ partes review.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in BOE Technology Group Co., Ltd. vs Samsung Display Co., Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Apple Inc.vsImberaTek, LLC
Apple and ImberaTek have settled their dispute over U.S. Patent 7,609,527 and jointly moved to terminate the pending IPR. The Board is asked to dismiss the pre‑institution proceeding on good‑cause grounds.
Terumo BCT, Inc.vsHaemonetics Corporation
Terumo BCT has filed an IPR petition seeking cancellation of all 30 claims of Haemonetics’ plasma‑collection patent, arguing they are obvious over a suite of older apheresis technologies. The petition lists nine statutory grounds under 35 U.S.C. §103, each tied to specific prior‑art references.
Alvotech USA Inc. et al.vsRegeneron Pharmaceuticals, Inc.
Alvotech petitions the PTAB to invalidate Regeneron’s ’036 patent covering high‑dose aflibercept eye‑treatment formulations, alleging obviousness and lack of written description. The petition relies on multiple Regeneron disclosures and external prior art. The Board has yet to rule.
3D Diagnostix, Inc.vsWatson Guide IP, LLC
3D Diagnostix petitions the PTAB to invalidate 13 claims of Watson Guide IP’s dental guide patent, alleging lack of written description, indefiniteness, and obviousness over multiple prior‑art references.
American Airlines, Inc. et al.vsIntellectual Ventures II LLC
The PTAB denied American Airlines and Southwest Airlines’ petition to institute an IPR against Intellectual Ventures’ ’326 patent covering high‑data‑rate multi‑channel WLAN. The Board found no reasonable likelihood of success on any of the 18 challenged claims.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.